03.13.18
To meet the growing demand for laboratory and clinical services solutions in the Mid-Atlantic Region, Frontage Laboratories, a global contract research organization (CRO) with headquarters in Exton, PA, has opened a new branch office located at 101 Carnegie Center in Princeton, NJ.
The Carnegie Center location adds 4,500 sq. ft. of office space to support the continued growth of both Frontage Laboratories and Frontage Clinical Services.
"We are very pleased to be able to add a third New Jersey location. This new site will allow us to better serve our pharmaceutical and biotech clients located in the Mid-Atlantic Region," said Song Li, founder and chief executive officer, Frontage Laboratories.
Frontage is a full-service early-stage CRO. With locations in the U.S. and China, the CRO has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, its full-service offerings include DMPK, bioanalysis using 60 LC-MS/MS instruments, analytical testing, product development, and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets.
The Carnegie Center location adds 4,500 sq. ft. of office space to support the continued growth of both Frontage Laboratories and Frontage Clinical Services.
"We are very pleased to be able to add a third New Jersey location. This new site will allow us to better serve our pharmaceutical and biotech clients located in the Mid-Atlantic Region," said Song Li, founder and chief executive officer, Frontage Laboratories.
Frontage is a full-service early-stage CRO. With locations in the U.S. and China, the CRO has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, its full-service offerings include DMPK, bioanalysis using 60 LC-MS/MS instruments, analytical testing, product development, and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets.
